• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen Announces the Appointment of Two New Board Members

    9/12/22 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email

    Board of Directors expanded in conjunction with the closing of the 3M Food Safety transaction

    LANSING, Mich., Sept. 12, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG), a leader in food and animal safety, announced today that it has appointed two new members to its Board of Directors: Jeffrey Capello and Aashima Gupta. The addition of Mr. Capello and Ms. Gupta was agreed by Neogen and 3M Company under the merger agreement for the 3M Food Safety transaction.

    "We are pleased to add these two experienced industry professionals to Neogen's Board of Directors," said Jim Borel, Neogen's Board Chair. "Their involvement in the global healthcare and biotechnology industries will be a significant benefit to Neogen as the company moves into this new era, and we are confident their expertise will be valuable as Neogen continues to grow."

    "The leadership and insight that both Jeff and Aashima will bring to our Board will help us continue to drive growth, enhance our global strategy, and create value for Neogen shareholders," said John Adent, Neogen's President and Chief Executive Officer. "I am looking forward to working closely with them as we enter this exciting time in Neogen's growth, creating new opportunities for the company, our customers, our shareholders, and our world."

    Jeff Capello is a senior finance executive with over 30 years of experience helping companies create significant value for their shareholders. He served as the Chief Financial Officer for publicly held and private equity-backed companies, including PerkinElmer, Boston Scientific, Ortho Clinical Diagnostic, Beacon Health Options, and Biogen. Jeff also served on the Board of Directors for several early-stage publicly held biotechnology companies as Audit Committee Chair, including Sirtris, OvaScience, and Flex Pharma. He currently is the Managing Member at Monomoy Advisors, a financial advisory firm that provides counsel to senior leadership on shareholder value creation strategies.

    Aashima Gupta is a strategic global leader with over 25 years of experience working at the intersection of health and technology, with extensive experience in complex large-scale enterprise environments. She worked in technology development across a number of organizations, including NIIT, Fidelity Investments, J.P. Morgan Chase, Apigee, and Kaiser Permanente. She joined Google in 2017 and serves as the Global Director for Healthcare Provider Solutions at Google Cloud. In this role, she sets the direction for the transformative healthcare solutions and leads engagement with key healthcare executives in growing, differentiating, and enhancing businesses through technology transformation, ranging from new models for care, revenue generation, and enhanced patient experiences. Aashima serves on the Board of Directors for HL7.org, IntelyCare, and the Board of Advisors for HIMSS NA. In 2019, she was recognized as the Most Influential Women in Healthcare by HIMSS and received the Top 100 FEMTech Award and Champion of Health Award.

    About Neogen

    Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

    CONTACT:

    Steve Quinlan, Chief Financial Officer



    517.372.9200, SQuinlan@Neogen.com 

     

    Cision View original content:https://www.prnewswire.com/news-releases/neogen-announces-the-appointment-of-two-new-board-members-301621954.html

    SOURCE NEOGEN Corporation

    Get the next $NEOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    SEC Filings

    View All

    SEC Form 10-Q filed by Neogen Corporation

    10-Q - NEOGEN CORP (0000711377) (Filer)

    4/9/26 4:03:42 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    4/9/26 7:01:47 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Leadership Update

    8-K - NEOGEN CORP (0000711377) (Filer)

    3/30/26 8:19:36 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen Reports Third Quarter Fiscal Year 2026 Financial Results

    Fiscal third quarter 2026 revenue of $211.2 million Food Safety revenue growth of 2.6%, Core Growth1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth1 of (8.7%) due primarily to third-party supplier challenges in the quarter Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09 Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million Adjusted EBITDA1 of $48.2 million; Adjusted EBITDA margins1 of 22.8% increases sequentially by 110 basis points Petrifilm® manufacturing transition remains on track for November FY27; Company has initiated

    4/9/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026

    Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company's performance for the third-quarter of fiscal year 2026. The conference call can be accessed by dialing: Toll-Free - North America: (1) 888-660-6264 International: (+1) 646-517-3975 Conference ID: 70064# The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "E

    3/30/26 8:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $252 worth of shares (23 units at $10.94) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/17/26 3:12:55 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Senior Vice President Ranalli Tamara A. was granted 101,626 shares (SEC Form 4)

    4/A - NEOGEN CORP (0000711377) (Issuer)

    1/29/26 10:30:09 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $252 worth of shares (23 units at $10.94) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/17/26 3:12:55 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,279 worth of shares (137 units at $9.33) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/16/26 9:04:01 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

    4/8/26 8:00:00 AM ET
    $CNTX
    $NEOG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Reports Third Quarter Fiscal Year 2026 Financial Results

    Fiscal third quarter 2026 revenue of $211.2 million Food Safety revenue growth of 2.6%, Core Growth1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth1 of (8.7%) due primarily to third-party supplier challenges in the quarter Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09 Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million Adjusted EBITDA1 of $48.2 million; Adjusted EBITDA margins1 of 22.8% increases sequentially by 110 basis points Petrifilm® manufacturing transition remains on track for November FY27; Company has initiated

    4/9/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026

    Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company's performance for the third-quarter of fiscal year 2026. The conference call can be accessed by dialing: Toll-Free - North America: (1) 888-660-6264 International: (+1) 646-517-3975 Conference ID: 70064# The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "E

    3/30/26 8:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care